MECOM and colorectal carcinoma: In conclusion, targeting the MAPK signal transduction pathway through the targeting of FGF9, FGF2, MECOM, PRKACB and PLA2G4C might increase tumor responsiveness to irinotecan and improve patient survival thus being therapeutically and prognostic significant in CRC patients.